Has Adele confirmed using Ozempic or any GLP-1 drug?

No. As of 2026, Adele has not confirmed using semaglutide (Ozempic/Wegovy), liraglutide (Saxenda), or any GLP-1 receptor agonist. She has attributed her weight loss to exercise and the Sirtfood Diet.

What is the Sirtfood Diet that Adele followed?

A two-phase diet emphasizing polyphenol-rich foods believed to activate sirtuin proteins. Phase one restricts calories to 1,000 per day for three days, then 1,500 for four days, combined with green juices. Evidence for sirtuin-specific weight loss benefits in humans remains limited per published reviews.

Could someone lose 100 pounds without medication?

Yes, though it is above average for behavioral interventions alone. Clinical trials show diet-plus-exercise programs typically produce 5% to 10% body weight loss over 12 months. Greater losses are documented but require sustained, high-adherence protocols, often with professional support.

What would a GLP-1 medication add to diet and exercise?

GLP-1 receptor agonists reduce appetite and slow gastric emptying. In the STEP 1 trial, semaglutide 2.4 mg weekly combined with lifestyle intervention produced ~15% body weight loss over 68 weeks, roughly triple the placebo-plus-lifestyle arm.

Why do people speculate about celebrities and GLP-1 drugs?

Rapid, visible weight loss in public figures often prompts speculation because the magnitude exceeds typical behavioral-only outcomes seen in clinical data. GLP-1 medications have become widely discussed since 2022, and retrospective speculation has been applied to earlier transformations like Adele's.

Adele Transformation Timeline: Public Photos, Public Statements, and the Medical Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Status: GLP-1 use is publicly speculated but not confirmed by Adele
Her stated methods: Sirtfood Diet, daily exercise (circuit training with Dalton Wong), therapy
Timeline: Visible changes emerged mid-2019; most dramatic difference noted by early 2020
Drug class discussed: GLP-1 receptor agonists (semaglutide, liraglutide)
Clinical relevance: Her case predates mainstream GLP-1 awareness, making it a frequent comparison point

The Public Record: What Adele Has Actually Said

Adele's weight loss became a media story in late 2019 when she posted a photo at Drake's birthday party showing a noticeably slimmer frame. By May 2020, an Instagram post on her 32nd birthday confirmed the extent of the change.

In her November 2021 interview with Oprah on CBS, Adele stated she began exercising to manage anxiety following her divorce from Simon Konecki. "It was never about losing weight," she said. "It was always about becoming strong and giving myself as much time every day without my phone." She credited daily workouts, often twice a day, with trainer Dalton Wong.

In a British Vogue cover story (October 2021), she described lifting weights and doing circuit training. She also referenced the Sirtfood Diet, a plan based on foods high in sirtuins (polyphenol-rich plants like kale, green tea, and dark chocolate), as part of her initial approach.

At no point in any verified interview has Adele confirmed using semaglutide, liraglutide, tirzepatide, or any other GLP-1 receptor agonist.

Where the GLP-1 Speculation Comes From

The speculation is circumstantial and media-driven. Several factors fueled it:

The speed and magnitude of the loss (roughly 100 lbs in under two years)
Timing that overlapped with growing off-label prescribing of liraglutide (Saxenda) and early semaglutide availability in the UK
Reports from unnamed sources in tabloids (none confirmed by Adele or her representatives)

The HealthRX Medical Team notes: speculation about a public figure's medication use based solely on physical appearance is not evidence. Rapid weight loss is achievable through caloric deficit and exercise, particularly at Adele's reported training volume of 5 to 7 sessions per week with a professional trainer.

Clinical Context: The Sirtfood Diet

The Sirtfood Diet, which Adele publicly endorsed, centers on foods claimed to activate sirtuin proteins (SIRT1 through SIRT7). These NAD-dependent deacetylases regulate cellular metabolism, inflammation, and aging pathways.

Evidence for the diet's weight loss claims is limited. A 2019 review in Advances in Nutrition found that while polyphenol-rich foods (resveratrol, EGCG from green tea) can activate SIRT1, the effect sizes on body composition in humans are modest. Caloric restriction itself activates sirtuins, making it difficult to separate the diet's specific food choices from its 1,000-calorie initial phase.

The first phase restricts intake to 1,000 kcal/day for three days, then 1,500 kcal/day for four days. This alone would produce significant water and glycogen loss in week one, independent of sirtuin activation.

Clinical Context: GLP-1 Receptor Agonists

Since Adele's case is so frequently discussed alongside GLP-1 medications, the HealthRX Medical Team provides the following clinical primer for readers evaluating the speculation.

Mechanism. GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) mimic the incretin hormone GLP-1, slowing gastric emptying, reducing appetite signaling in the hypothalamus, and improving insulin sensitivity. A 2021 NEJM trial (STEP 1) showed 2.4 mg weekly semaglutide produced mean weight loss of 14.9% over 68 weeks versus 2.4% with placebo.

Typical timeline. Most patients on semaglutide notice appetite reduction within 2 to 4 weeks. Weight loss velocity peaks around months 3 to 6, with plateau typically by month 12 to 16. Adele's reported timeline (visible change over 18+ months) is consistent with either pharmacological intervention or sustained caloric deficit with high exercise volume.

Side effect profile. The most common adverse effects are gastrointestinal: nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%), per FDA prescribing information for Wegovy. Pancreatitis, gallbladder disease, and potential thyroid C-cell tumor risk (observed in rodents) are listed warnings.

Dose ranges. Semaglutide for weight management is titrated from 0.25 mg weekly to a maintenance dose of 2.4 mg weekly. Liraglutide (Saxenda) uses daily injections titrated to 3.0 mg. Tirzepatide (Zepbound), a dual GIP/GLP-1 agonist, is dosed at 5 mg to 15 mg weekly.

Comparing Achievable Rates of Loss

Is 100 pounds in roughly 18 to 24 months achievable without pharmacological support? The clinical answer is yes, though it requires sustained adherence.

A 2014 meta-analysis in the Journal of the American Medical Association found that behavioral weight loss programs (diet plus exercise plus counseling) produce average losses of 5% to 10% of body weight over 12 months. For someone starting at approximately 230 to 250 lbs (Adele's estimated starting weight based on public photos), a 100-lb loss represents 40% to 43% of body weight. This exceeds typical behavioral-only outcomes, which is precisely why speculation arose.

With a personal trainer, chef, and the financial resources to optimize every variable, higher-than-average results become more plausible. The HealthRX Medical Team position: her reported methods (high exercise frequency, caloric restriction, professional support) could produce this result, but the magnitude sits at the upper boundary of what behavioral interventions typically achieve in clinical literature.

The HealthRX Medical Team Take

We cannot and do not confirm Adele's use of any GLP-1 medication. What we can say:

Her publicly stated methods (caloric restriction via the Sirtfood Diet, daily high-intensity training, professional coaching) are legitimate weight loss strategies with real clinical backing.
The magnitude of loss is unusual for behavioral-only approaches in published literature, though published data generally reflects average adherence without elite-level professional support.
GLP-1 receptor agonists were available in the UK during her transformation period (liraglutide was approved by the EMA in 2015; semaglutide 2.4 mg received EMA approval in January 2022, but lower doses were available earlier for diabetes).
Speculation without confirmation remains speculation. Physical appearance alone is not diagnostic evidence of pharmaceutical use.

For patients interested in what Adele's case means for their own weight management: consult a physician about evidence-based options. Both behavioral programs and GLP-1 medications have strong trial data. The choice depends on individual metabolic profile, comorbidities, insurance coverage, and personal preference.

Frequently asked questions

›

References

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
FDA. Wegovy (semaglutide) prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
Pallauf K, et al. Nutrition and healthy ageing: calorie restriction or polyphenol-rich "MediterrAsian" diet? Adv Nutr. 2019;10(Suppl 4):S391-S403. https://pubmed.ncbi.nlm.nih.gov/30785610/
Wadden TA, et al. Weight loss with naltrexone SR/bupropion SR combination therapy. JAMA. 2014;311(3):310. https://jamanetwork.com/journals/jama/fullarticle/1900510
Adele interview with Oprah Winfrey. CBS One Night Only Special. November 2021.
Adele cover story. British Vogue. November 2021.